Magnesium plus prochlorperazine for migraine relief
Evaluating the Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines in the Emergency Department
This trial will test whether adding IV magnesium to IV prochlorperazine helps adults with migraine get better pain relief in the emergency department.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Oak Lawn, Illinois) |
| Trial ID | NCT06904287 on ClinicalTrials.gov |
What this trial studies
This is a prospective, randomized, double-blinded Phase 3 trial comparing IV magnesium plus IV prochlorperazine versus IV prochlorperazine with placebo for treating migraine in the emergency department. Adults presenting with a primary diagnosis of migraine and a prior history of migraine are eligible if they can consent and meet clinical criteria. The study measures headache pain reduction and monitors safety and side effects after treatment. Results aim to determine whether magnesium adds meaningful benefit when given with prochlorperazine for acute migraine care.
Who should consider this trial
Good fit: Adults aged 18 or older who present to the ED with a primary migraine diagnosis, have a history of migraine with typical features, speak English, and can give informed consent are ideal candidates.
Not a fit: People who are pregnant, have renal insufficiency, myasthenia gravis, an allergy to the study drug, recent magnesium use within 48 hours, or who do not have a primary migraine are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, adding magnesium could provide faster or stronger pain relief for ED patients treated with prochlorperazine.
How similar studies have performed: Previous smaller and ED-based trials have suggested IV magnesium can help with migraine pain but results have been mixed, so larger trials are needed for clearer evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years or older * Able to provide informed consent * English speaking * Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated with nausea), AND with a clinical exclusion of migraine mimics Exclusion Criteria: * Pregnancy defined as a positive urine HCG * Allergy or sensitivity to study drug * Stated history of renal insufficiency * Documented history of myasthenia gravis * Consumption of study drug within 48 hours prior to enrollment * Previously enrolled in this trial during a different patient encounter
Where this trial is running
Oak Lawn, Illinois
- Advocate Christ Medical Center Emergency Department — Oak Lawn, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Ryan McKillip, MD — Wake Forest University Health Sciences
- Study coordinator: Ryan McKillip, MD
- Email: ryan.mckillip@aah.org
- Phone: 708-684-6230
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.